Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
Bakiye Göker Bağca, Çığır Biray Avci
Cytokine & Growth Factor Reviews (2020) Vol. 54, pp. 51-61
Open Access | Times Cited: 106

Showing 1-25 of 106 citing articles:

The signal pathways and treatment of cytokine storm in COVID-19
Lan Yang, Xueru Xie, Zikun Tu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 508
Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome
Lawrence B. Afrin, Leonard B. Weinstock, Gerhard J. Molderings
International Journal of Infectious Diseases (2020) Vol. 100, pp. 327-332
Open Access | Times Cited: 283
STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters
Robbert Boudewijns, Hendrik Jan Thibaut, Suzanne J. F. Kaptein, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 275
Integrated intra‐ and intercellular signaling knowledge for multicellular omics analysis
Dénes Türei, Alberto Valdeolivas, Lejla Gul, et al.
Molecular Systems Biology (2021) Vol. 17, Iss. 3
Open Access | Times Cited: 242
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition
Hua Zhu, Zhihong Jian, Yi Zhong, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 228
The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options
Shalki Choudhary, Kajal Sharma, Om Silakari
Microbial Pathogenesis (2020) Vol. 150, pp. 104673-104673
Open Access | Times Cited: 198
COVID-19 and the role of cytokines in this disease
Amin Hasanvand
Inflammopharmacology (2022) Vol. 30, Iss. 3, pp. 789-798
Open Access | Times Cited: 95
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 82
The role of artificial intelligence in pandemic responses: from epidemiological modeling to vaccine development
Mayur Suresh Gawande, N. N. Zade, Praveen Kumar, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access | Times Cited: 4
Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies
Xi Wang, Yuanxun Wang, Xuemin Li, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 10, pp. 1650-1671
Open Access | Times Cited: 104
Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19
Jayanta Talukdar, Bhaskar Bhadra, Tomal Dattaroy, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 132, pp. 110886-110886
Open Access | Times Cited: 93
Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19
Angela E. Peter, B. V. Sandeep, B. Ganga Rao, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 84
Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review
Suwen Hu, Songwei Jiang, Qi Xiang, et al.
Drug Development Research (2021) Vol. 83, Iss. 1, pp. 16-54
Open Access | Times Cited: 61
Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options
Yasaman Nazerian, Mobina Ghasemi, Younes Yassaghi, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109428-109428
Open Access | Times Cited: 52
Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy
Mahdi Eskandarian Boroujeni, Agata Sekrecka, Aleksandra Antonczyk, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 50
Neurological complications associated with Covid‐19; molecular mechanisms and therapeutic approaches
Mohammad Mahboubi Mehrabani, Mohammad Sobhan Karvandi, Pedram Maafi, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 6
Open Access | Times Cited: 47
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
Yujie Jiang, Tingmei Zhao, Xueyan Zhou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 46
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
Reza Elahi, Parsa Karami, Amir Hossein Heidary, et al.
International Immunopharmacology (2022) Vol. 105, pp. 108536-108536
Open Access | Times Cited: 45
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
MeiLan K. Han, Martti Antila, Joachim H. Ficker, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 5, pp. e351-e361
Open Access | Times Cited: 40
Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in Lung inflammatory disease
Manish Purohit, Gaurav Gupta, Obaid Afzal, et al.
Chemico-Biological Interactions (2023) Vol. 371, pp. 110334-110334
Closed Access | Times Cited: 31
Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway
Songtao Gu, Jingjing Liang, Jianwei Zhang, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2195-2195
Open Access | Times Cited: 24
SOCS, Intrinsic Virulence Factors, and Treatment of COVID-19
Howard M. Johnson, Alfred S. Lewin, Chulbul M. Ahmed
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 53
Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics
Tian‐Hua Wei, Meng‐Yi Lu, Sihui Yao, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 7
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease‐2019 (COVID‐19): A systematic review and meta‐analysis
Zhiwei Lin, Jianyi Niu, Yifan Xu, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1523-1534
Open Access | Times Cited: 41
Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy
Mohamad Mahjoor, Golnaz Mahmoudvand, Simin Farokhi, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top